Fisher Asset Management LLC Invests $29,000 in Precigen, Inc. (NASDAQ:PGEN)

Fisher Asset Management LLC bought a new position in Precigen, Inc. (NASDAQ:PGEN) during the 4th quarter, HoldingsChannel reports. The fund bought 21,800 shares of the biotechnology company’s stock, valued at approximately $29,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PGEN. Patient Capital Management LLC lifted its stake in shares of Precigen by 16.2% in the fourth quarter. Patient Capital Management LLC now owns 15,983,700 shares of the biotechnology company’s stock worth $21,418,000 after buying an additional 2,230,524 shares in the last quarter. Panagora Asset Management Inc. bought a new position in Precigen during the fourth quarter valued at approximately $407,000. Emfo LLC lifted its position in Precigen by 22.2% during the fourth quarter. Emfo LLC now owns 519,475 shares of the biotechnology company’s stock valued at $696,000 after purchasing an additional 94,475 shares during the period. Opaleye Management Inc. lifted its position in Precigen by 9.0% during the fourth quarter. Opaleye Management Inc. now owns 1,012,500 shares of the biotechnology company’s stock valued at $1,357,000 after purchasing an additional 84,000 shares during the period. Finally, Diversified Trust Co bought a new position in Precigen during the fourth quarter valued at approximately $39,000. Institutional investors own 33.51% of the company’s stock.

Precigen Trading Down 7.2 %

PGEN opened at $1.55 on Thursday. Precigen, Inc. has a 1-year low of $0.84 and a 1-year high of $1.88. The company has a market capitalization of $391.25 million, a PE ratio of -3.97 and a beta of 1.88. The firm’s 50 day simple moving average is $1.46 and its two-hundred day simple moving average is $1.42.

Precigen (NASDAQ:PGEN) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.54 million. Precigen had a negative return on equity of 65.36% and a negative net margin of 1,781.72%. During the same quarter in the previous year, the business posted ($0.10) earnings per share. Equities analysts forecast that Precigen, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PGEN has been the topic of a number of research analyst reports. Stifel Nicolaus increased their price objective on shares of Precigen from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, June 3rd. StockNews.com upgraded shares of Precigen to a “sell” rating in a research report on Tuesday, May 21st. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Precigen in a research report on Monday, June 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Precigen in a research report on Wednesday, May 15th. Finally, JPMorgan Chase & Co. downgraded shares of Precigen from a “neutral” rating to an “underweight” rating in a research report on Friday, March 22nd. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, Precigen presently has an average rating of “Hold” and a consensus price target of $10.00.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.